IMMUTEP SECURES SECOND UNITED STATES PATENT GRANT FOR EFTILAGIMOD ALPHA IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR Sydney, AUSTRALIA, March 09, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...